Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer
05:43pm, Friday, 29'th Sep 2023
Chris Shibutani, Goldman Sachs Senior Analyst, joins 'Closing Bell Overtime' to talk his top picks in the biotech sectors.
Don't Miss the Boom: 3 ETFs Set to Explode Higher
03:30pm, Wednesday, 27'th Sep 2023
The global economy faces significant uncertainty. High-interest rates, persistent inflation and geopolitical crises all threaten to roil financial markets.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:32am, Monday, 18'th Sep 2023
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched
Best Healthcare ETFs to Buy Now
03:53pm, Thursday, 24'th Aug 2023
The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
04:11pm, Tuesday, 15'th Aug 2023
A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:34am, Tuesday, 18'th Jul 2023
Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Is Now the Right Time to Embrace Biotech ETFs?
12:34pm, Wednesday, 12'th Jul 2023
Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.
ARKG: Outperforming XBI, Reasonably Valued With Technical Upside Potential In 2H
01:07am, Sunday, 02'nd Jul 2023
ARKG: Outperforming XBI, Reasonably Valued With Technical Upside Potential In 2H
XBI: A Vehicle For The Transformative Benefits Of Artificial Intelligence Within Biotechnology
04:59am, Saturday, 01'st Jul 2023
Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors. The
Buy This ETF Before June Runs Out
12:00pm, Friday, 16'th Jun 2023
Subscribers to Chart of the Week received this commentary on Sunday, June 11.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:34am, Monday, 29'th May 2023
Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:40am, Thursday, 18'th May 2023
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched
XBI: A Pure Play Biotech ETF In Need Of A Hedge
03:36am, Thursday, 18'th May 2023
Several ETFs exist offering investors concentrated biotech exposure that varies in stock selection and weighting schemes. While all of the choices exhibit 90%+ exposure to biotech stocks, only XBI is
ETF flows point to ‘skittish' investors as it's ‘a little unwieldy out there' after Fed rate hikes
03:50pm, Thursday, 04'th May 2023
Hello! In this week's ETF Wrap, I caught up with The ETF Store's Nate Geraci and State Street's Matthew Bartolini on flows as investors worry about a potential recession and try to discern the Fed's n
VettaFi Voices On: Smart Beta and Equal-Weight ETFs
02:36pm, Friday, 28'th Apr 2023
This week, the VettaFi Voices gather around the water cooler and talk smart beta and equal weight ETFs.
